Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Open Access
- 5 January 2025
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (7) , 1093-1101
Abstract
Positron emission tomography (PET) is frequently used to obtain target occupancy (%TO) of central nervous system (CNS) drug candidates during clinical development. Obtaining %TO with PET can be particularly powerful when the %TO associated with efficacy is known for a protein target. Using the radiotracer [18F]AV-133, the relationship between plasma concentration (PK) and %TO of NBI-750142, an experimental inhibitor of the vesicular monoamine transporter type 2 (VMAT2) was obtained in both nonhuman primate (NHP) and human. This work established [18F]AV-133 PET as capable of providing a VMAT2 inhibitor PK-%TO relationship that translated from NHP to human. To establish the VMAT2%TO benchmark, PET was performed in NHP with NBI-98782, the main active metabolite of valbenazine, and this PK-%TO relationship was used to estimate VMAT2%TO at NBI-98782 exposures associated with valbenazine therapeutic effects in the treatment of tardive dyskinesia (TD). This work defined 85–90% as the VMAT2%TO achieved by exposures associated with daily dosing with 80 mg valbenazine, a dosing regimen known to exhibit a large effect size in the treatment of TD and in the treatment of chorea associated with Huntington’s Disease. NBI-750142 was estimated to achieve 36–78% VMAT2 target occupancy at acceptable doses, indicating potential inferiority in conferring clinical benefit compared to valbenazine. It is recommended that the %TO benchmark of valbenazine derived from [18F]AV-133 PET serve as a gold standard biomarker to evaluate novel VMAT2 inhibitors undergoing clinical development.Keywords
Funding Information
- Neurocrine Biosciences, Inc.
This publication has 45 references indexed in Scilit:
- In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrationsNuclear Medicine and Biology, 2010
- Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging RadiotracersNeuropsychopharmacology, 2009
- The 'atypicality' of antipsychotics: a concept re-examined and re-definedNature Reviews Drug Discovery, 2009
- Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [11C]DASB Positron Emission Tomography StudyAmerican Journal of Psychiatry, 2004
- VMAT2 binding is elevated in dopa‐responsive dystonia: Visualizing empty vesicles by PETSynapse, 2003
- Graphical analysis of PET data applied to reversible and irreversible tracersNuclear Medicine and Biology, 2000
- Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode SchizophreniaAmerican Journal of Psychiatry, 2000
- Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects.1999
- Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transportersNuclear Medicine and Biology, 1996
- Chemistry and Pharmacology of CNS Depressants Related to 4-(4-Hydroxy-4-phenylpiperidino)butyrophenone Part I--Synthesis and screening data in miceJournal of Medicinal Chemistry, 1959